Ultragenyx Reports Third Quarter 2019 Financial Results and Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ultragenyx Reports Third Quarter 2019 Financial Results and Corporate Update

Ultragenyx Pharma (RARE) Misses Q3 EPS by 28c

November 5, 2019 4:53 PM EST

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.96), $0.28 worse than the analyst estimate of ($1.68). Revenue for the quarter came in at $25.8 million versus the consensus estimate of $29.12 million.

Strong Crysvita® (burosumab) Launch Continues with Approximately 1,130 Patients on Reimbursed... More